Abstract: It forms an object of the present invention a method to obtain monoclonal antibodies, or fragments or conjugates thereof, which bind with high affinity to a target protein which is a protein specifically expressed in local and metastatic tumors, preferably said target protein being Trop-2, wherein said method comprises: —making available an immunogenic material, wherein the immunogenic material is selected in the group comprising the target protein, fragments and conjugates thereof produced in different organisms, including tumor cells that naturally express the processed target protein and mammalian transformed and tumor cells, insect cells, yeast cells, bacterial cells that have been transfected with vectors that express the target protein and fragments thereof, also as fusion proteins with other sequences; —administering to a non-human animal one of said immunogenic material.

Abstract: A method for the diagnosis and treatment of cancer is characterized by the fact that an increase in the levels of Trop-2 in the tumor, as compared to the levels of Trop-2 in the corresponding normal tissues, constitutes a biological marker that can predict the tumor response to anticancer therapy with drugs directed against components of the signalling network of Trop-2, including but not limited to drugs which inhibit CD9, Akt and molecules of the tetraspanin signalling network. More particularly, the use of the biological marker Trop-2 is disclosed in the screening of new compounds, and in the clinical setting as an indicator for the use of anticancer drugs targeted against molecules of the signalling network of Trop-2, including but not limited to drugs that inhibit CD9, Akt and molecules of the tetraspanin signalling network.

Abstract: The present invention refers to humanized anti-Trop-2 antibodies and their fragments, derivatives and conjugates that are able to recognise and bind with high affinity distinct regions of the Trop-2 molecule. The present invention also teaches the use of such antibodies and of pharmaceutical compositions thereof for diagnosis and therapy of human pathologies, in particular cancer.

Abstract: The present invention consists of a method for non-invasive monitoring of the presence of tumor disease in a patient, characterized by measuring the levels of the circulating Trop-2 protein in unfractionated serum obtained from the tumor patient. This method also allows non-invasive monitoring of tumor progression or regression, by comparing the levels of the Trop-2 biomarker measured in unfractionated serum samples taken at different times from the same patient. This method also allows the non-invasive monitoring of tumor response to therapy, wherein the levels of the Trop-2 biomarker are measured in unfractionated serum samples taken from the same patient before, during and after cancer therapy. It is part of the present invention a method for measuring the circulating Trop-2 protein in unfractionated serum.

Abstract: The present invention refers to humanized anti-Trop-2 antibodies and their fragments, derivatives and conjugates that are able to recognise and bind with high affinity distinct regions of the Trop-2 molecule. The present invention also teaches the use of such antibodies and of pharmaceutical compositions thereof for diagnosis and therapy of human pathologies, in particular cancer.

Abstract: The present invention teaches anti-Trop-2 monoclonal antibodies with high affinity and able to recognize different regions of the Trop-2 molecule, and uses thereof in the treatment and diagnosis of tumors, such as for example endometrium, breast, head and neck, colon-rectum, stomach, lung, ovary, prostate, pancreas, kidney, cervix and bladder (urothelial) tumors.

Abstract: The invention concerns RNA oligonucleotide sequences or sequences that are transcribed into RNA or analogous molecules able to silence the expression of the CYCLIN D1/TROP2 chimeric mRNA and their use in the treatment and the prevention of tumors.

Abstract: An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumor selectivity.

Abstract: The present invention teaches anti-Trop-2 monoclonal antibodies with high affinity and able to recognize different regions of the Trop-2 molecule, and uses thereof in the treatment and diagnosis of tumors, such as for example endometrium, breast, head and neck, colon-rectum, stomach, lung, ovary, prostate, pancreas, kidney, cervix and bladder (urothelial) tumors.

Abstract: The invention concerns RNA oligonucleotide sequences or sequences that are transcribed into RNA or analogous molecules able to silence the expression of the CYCLIN D1/TROP2 chimeric mRNA and their use in the treatment and the prevention of tumors.

Abstract: An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumour selectivity.